Arrowhead Pharmaceuticals
ARWR · NASDAQ
$58.92+$1.69 (+2.95%)TodayMarket closed ·
Prev close $57.23
EPS: actual vs estimate
Beat the estimate in 3 of the last 8 quarters, by 503.8% on average
Next report: , after the market closes
- Quarter
- Q4 FY26
- EPS estimate
- -$1.52
- Revenue estimate
- $61.60M
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q3 FY26 | -$1.35 | -$1.36 | −1.0% |
| Q2 FY26 | -$1.21 | -$0.93 | +23.2% |
| Q1 FY26 | $0.2581 | $0.22 | −14.8% |
| Q4 FY25 | -$0.2456 | -$0.18 | +26.7% |
| Q3 FY25 | -$1.05 | -$1.26 | −20.5% |
| Q2 FY25 | -$0.202 | $2.75 | +1461.4% |
| Q1 FY25 | -$0.4464 | -$1.39 | −211.4% |
| Q4 FY24 | -$1.07 | -$1.37 | −28.2% |
Earnings calls
- Special Call - Arrowhead Pharmaceuticals, Inc.
- H.C. Wainwright 28th Annual Global Investment Conference
- Morgan Stanley 24th Annual Global Healthcare Conference
- 12th Annual Cantor Fitzgerald Global Healthcare Conference
- Special Call - Arrowhead Pharmaceuticals, Inc.
- ARWR - Earnings call Q3 2026
- Special Call - Arrowhead Pharmaceuticals, Inc.
- Goldman Sachs 47th Annual Global Healthcare Conference 2026
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.